UCS15A, a novel small molecule, SH3 domain-mediated protein-protein interaction blocking drug
- PMID:11960376
- DOI: 10.1038/sj.onc.1205271
UCS15A, a novel small molecule, SH3 domain-mediated protein-protein interaction blocking drug
Abstract
Protein-protein interactions play critical regulatory roles in mediating signal transduction. Previous studies have identified an unconventional, small-molecule, Src signal transduction inhibitor, UCS15A. UCS15A differed from conventional Src-inhibitors in that it did not alter the levels or the tyrosine kinase activity of Src. Our studies suggested that UCS15A exerted its Src-inhibitory effects by a novel mechanism that involved the disruption of protein-protein interactions mediated by Src. In the present study we have examined the ability of UCS15A to disrupt the interaction of Src-SH3 with Sam68, both in vivo and in vitro. This ability of UCS15A was not restricted to Src-SH3 mediated protein-protein interactions, since the drug was capable of disrupting the in vivo interactions of Sam68 with other SH3 domain containing proteins such as Grb2 and PLCgamma. In addition, UCS15A was capable of disrupting other typical SH3-mediated protein-protein interactions such as Grb2-Sos1, cortactin-ZO1, as well as atypical SH3-mediated protein-protein interactions such as Grb2-Gab1. However, UCS15A was unable to disrupt the non-SH3-mediated protein-protein interactions of beta-catenin, with E-cadherin and alpha-catenin. In addition, UCS15A had no effect on the SH2-mediated interaction between Grb2 and activated Epidermal Growth Factor receptor. Thus, the ability of UCS15A, to disrupt protein-protein interactions appeared to be restricted to SH3-mediated protein-protein interactions. In this regard, UCS15A represents the first example of a non-peptide, small molecule agent capable of disrupting SH3-mediated protein-protein interactions. In vitro analyses suggested that UCS15A did not bind to the SH3 domain itself but rather may interact directly with the target proline-rich domains.
Similar articles
- UCS15A, a non-kinase inhibitor of Src signal transduction.Sharma SV, Oneyama C, Yamashita Y, Nakano H, Sugawara K, Hamada M, Kosaka N, Tamaoki T.Sharma SV, et al.Oncogene. 2001 Apr 19;20(17):2068-79. doi: 10.1038/sj.onc.1204296.Oncogene. 2001.PMID:11360191
- Coupling of the murine protein tyrosine phosphatase PEST to the epidermal growth factor (EGF) receptor through a Src homology 3 (SH3) domain-mediated association with Grb2.Charest A, Wagner J, Kwan M, Tremblay ML.Charest A, et al.Oncogene. 1997 Apr 10;14(14):1643-51. doi: 10.1038/sj.onc.1201008.Oncogene. 1997.PMID:9135065
- Sam68 associates with the SH3 domains of Grb2 recruiting GAP to the Grb2-SOS complex in insulin receptor signaling.Najib S, Sánchez-Margalet V.Najib S, et al.J Cell Biochem. 2002;86(1):99-106. doi: 10.1002/jcb.10198.J Cell Biochem. 2002.PMID:12112020
- Membrane-targeting of signalling molecules by SH2/SH3 domain-containing adaptor proteins.Buday L.Buday L.Biochim Biophys Acta. 1999 Jul 6;1422(2):187-204. doi: 10.1016/s0304-4157(99)00005-2.Biochim Biophys Acta. 1999.PMID:10393272Review.
- Progress towards the development of SH2 domain inhibitors.Kraskouskaya D, Duodu E, Arpin CC, Gunning PT.Kraskouskaya D, et al.Chem Soc Rev. 2013 Apr 21;42(8):3337-70. doi: 10.1039/c3cs35449k. Epub 2013 Feb 11.Chem Soc Rev. 2013.PMID:23396540Review.
Cited by
- Grb2 signaling in cell motility and cancer.Giubellino A, Burke TR Jr, Bottaro DP.Giubellino A, et al.Expert Opin Ther Targets. 2008 Aug;12(8):1021-33. doi: 10.1517/14728222.12.8.1021.Expert Opin Ther Targets. 2008.PMID:18620523Free PMC article.Review.
- Small molecule inhibitors of the HIV-1 virulence factor, Nef.Smithgall TE, Thomas G.Smithgall TE, et al.Drug Discov Today Technol. 2013 Dec;10(4):e523-9. doi: 10.1016/j.ddtec.2013.07.002.Drug Discov Today Technol. 2013.PMID:24451644Free PMC article.Review.
- High-Affinity Interactions of the nSH3/cSH3 Domains of Grb2 with the C-Terminal Proline-Rich Domain of SOS1.Liao TJ, Jang H, Nussinov R, Fushman D.Liao TJ, et al.J Am Chem Soc. 2020 Feb 19;142(7):3401-3411. doi: 10.1021/jacs.9b10710. Epub 2020 Feb 4.J Am Chem Soc. 2020.PMID:31970984Free PMC article.
- Comparative genomic assessment of novel broad-spectrum targets for antibacterial drugs.White TA, Kell DB.White TA, et al.Comp Funct Genomics. 2004;5(4):304-27. doi: 10.1002/cfg.411.Comp Funct Genomics. 2004.PMID:18629165Free PMC article.
- Molecular Dynamics model of peptide-protein conjugation: case study of covalent complex between Sos1 peptide and N-terminal SH3 domain from Grb2.Luzik DA, Rogacheva ON, Izmailov SA, Indeykina MI, Kononikhin AS, Skrynnikov NR.Luzik DA, et al.Sci Rep. 2019 Dec 27;9(1):20219. doi: 10.1038/s41598-019-56078-7.Sci Rep. 2019.PMID:31882608Free PMC article.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous